Oncotarget

October 23, 2018

View Archive »

About The Cover

The cover for issue 83 of Oncotarget features Figure 4, "Trametinib and the combined treatment of JQ1 and trametinib inhibit ATC cell migration," by Zhu, et al.

Table of Contents

Editorial

New insights in melanoma resistance to BRAF inhibitors: a role for microRNAs

New insights in melanoma resistance to BRAF inhibitors: a role for microRNAs

https://doi.org/10.18632/oncotarget.26244

Marta Díaz-Martínez, Lucía Benito-Jardón,  and Joaquin Teixidó
35374-35375
PDF  |  How to cite

Targeting age-related inflammation in myelodysplastic syndromes

Targeting age-related inflammation in myelodysplastic syndromes

https://doi.org/10.18632/oncotarget.26266

Yang Mei,  and Peng Ji
35376-35377
PDF  |  How to cite

Research Papers

NOX2 oxidase expressed in endosomes promotes cell proliferation and prostate tumour development

NOX2 oxidase expressed in endosomes promotes cell proliferation and prostate tumour development

https://doi.org/10.18632/oncotarget.26237

Ian P. Harrison, Antony Vinh, Ian R.D. Johnson, Raymond Luong, Grant R. Drummond, Christopher G. Sobey, Tony Tiganis, Elizabeth D. Williams, John J. O’Leary, Doug A. Brooks,  and Stavros Selemidis
35378-35393
Abstract  |  PDF  |  HTML  |  Supplementary Information  |  How to cite

Personalized identification of tumor-associated immunogenic neoepitopes in hepatocellular carcinoma in complete remission after sorafenib treatment

Personalized identification of tumor-associated immunogenic neoepitopes in hepatocellular carcinoma in complete remission after sorafenib treatment

https://doi.org/10.18632/oncotarget.26247

Sindy Vrecko, David Guenat, Patricia Mercier-Letondal, Hugues Faucheu, Magalie Dosset, Bernard Royer, Jeanne Galaine, Romain Boidot, Stefano Kim, Marine Jary, Olivier Adotévi, Christophe Borg,  and Yann Godet
35394-35407
Abstract  |  PDF  |  HTML  |  Supplementary Information  |  How to cite

Synergistic effects of BET and MEK inhibitors promote regression of anaplastic thyroid tumors

Synergistic effects of BET and MEK inhibitors promote regression of anaplastic thyroid tumors

https://doi.org/10.18632/oncotarget.26253

Xuguang Zhu, Erik Holmsen, Sunmi Park, Mark C. Willingham, Jun Qi,  and Sheue-yann Cheng
35408-35421
Abstract  |  PDF  |  HTML  |  How to cite  |  Press Release

The adaptive regulation of thiamine pyrophosphokinase-1 facilitates malignant growth during supplemental thiamine conditions

The adaptive regulation of thiamine pyrophosphokinase-1 facilitates malignant growth during supplemental thiamine conditions

https://doi.org/10.18632/oncotarget.26259

Hunter C. Jonus, Bradley S. Hanberry, Shivani Khatu, Jaeah Kim, Hendrik Luesch, Long H. Dang, Michael G. Bartlett,  and Jason A. Zastre
35422-35438
Abstract  |  PDF  |  HTML  |  Supplementary Information  |  How to cite

Meta-Analysis

Systematic review and meta-analysis of third-line salvage therapy for the treatment of advanced non-small-cell lung cancer: A meta-analysis of randomized controlled trials

Systematic review and meta-analysis of third-line salvage therapy for the treatment of advanced non-small-cell lung cancer: A meta-analysis of randomized controlled trials

https://doi.org/10.18632/oncotarget.24967

Nan Zhang, Nan Guo, Liang Tian,  and Zhigang Miao
35439-35447
Abstract  |  PDF  |  HTML  |  Supplementary Information  |  How to cite

Reviews

Naturally occurring compounds as pancreatic cancer therapeutics

Naturally occurring compounds as pancreatic cancer therapeutics

https://doi.org/10.18632/oncotarget.26234

Ines Lohse, Erin Wildermuth,  and Shaun P. Brothers
35448-35457
Abstract  |  PDF  |  HTML  |  How to cite

Constitutional mismatch repair-deficiency: current problems and emerging therapeutic strategies

Constitutional mismatch repair-deficiency: current problems and emerging therapeutic strategies

https://doi.org/10.18632/oncotarget.26249

Malak Abedalthagafi
35458-35469
Abstract  |  PDF  |  HTML  |  How to cite


Copyright © 2024 Impact Journals, LLC
Impact Journals is a registered trademark of Impact Journals, LLC